Scarica l'app Stockscreener
86.34
0.17%
-0.15
Dopo l'orario di chiusura:
86.00
-0.34
-0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$86.49
Aprire:
$85.87
Volume 24 ore:
738.71K
Relative Volume:
0.36
Capitalizzazione di mercato:
$12.20B
Reddito:
$622.01M
Utile/perdita netta:
$-271.86M
Rapporto P/E:
-40.19
EPS:
-2.1484
Flusso di cassa netto:
$-45.87M
1 W Prestazione:
+1.68%
1M Prestazione:
-3.63%
6M Prestazione:
+32.63%
1 anno Prestazione:
+208.36%
Intervallo 1D:
$84.20
$86.96
Intervallo di 1 settimana:
$80.75
$86.96
Portata 52W:
$27.10
$95.49
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
86.34 | 12.36B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals director sells $173,920 in stock - Investing.com
Arrowhead Pharmaceuticals (ARWR) Director Adeoye Olukotun Sells 2,000 Shares - GuruFocus
Arrowhead (ARWR) Stock: Slides 3.28% to $86.47 in the Latest Reading; Technical Setup: the $82.15 to $90.79 Range Remains in Focus at the CloseHigh Dividend Factor - Vinanet
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ARWR - TradingView
Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares - Stock Titan
Arrowhead (NASDAQ: ARWR) director to sell 11,600 shares - Stock Titan
ARWR Looks 53.4% Overvalued on GF Value™ - GuruFocus
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides - Arrowhead Pharmaceuticals, Inc.
ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks - TradingView
Arrowhead Pharmaceuticals Earnings Call Signals Confident Expansion - TipRanks
Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits
Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants - Stock Titan
Arrowhead Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | HDP1 | US04280A1007 - marketscreener.com
Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight - Sahm
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis: A Biotech Gem with 24.74% Upside - DirectorsTalk Interviews
Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses - simplywall.st
FY2026 Earnings Estimate for ARWR Issued By HC Wainwright - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for ARWR - MarketBeat
Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - marketbeat.com
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress - simplywall.st
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside - TradingView
Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... - Yahoo Finance
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights - marketbeat.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results - MarketBeat
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arrowhead Pharmaceuticals Inc.R (HDP1.DU) Q3 FY2026 earnings call transcript - Yahoo Finance
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher - Arrowhead Pharmaceuticals, Inc.
The Manufacturers Life Insurance Company Has $10.06 Million Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
FDA voucher could put Arrowhead's planned drug filing on a six-month review track - Stock Titan
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)August 3, 2026 - BioSpace
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh - TradingView
Janus Henderson Group PLC Acquires 156,544 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Vanguard unit discloses 6.38M Arrowhead (ARWR) shares, a 4.53% stake - Stock Titan
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. $ARWR Position Cut by Arrowstreet Capital Limited Partnership - MarketBeat
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $105.4, Implies 23% Upside - TradingView
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - BioSpace
Arrowhead Pharmaceuticals Advances Zodasiran Study for HoFH Trea - GuruFocus
Arrowhead Pharmaceuticals Inc - TradingKey
BlackRock discloses 10.1% Arrowhead Pharmaceuticals (ARWR) stake in latest 13G/A - Stock Titan
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Stocktwits
Arrowhead Pharmaceuticals (ARWR) Completes Enrollment in YOSEMITE Trial - GuruFocus
H.C. Wainwright raises Arrowhead Pharma price target to $115 on trial data - Investing.com Canada
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arrowhead Pharmaceuticals Inc Azioni (ARWR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PERRY MICHAEL S | Director |
Aug 18 '26 |
Sale |
87.30 |
11,600 |
1,012,680 |
111,459 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):